Trial · NCT04856930
Adverse event totals21
The totals the trial posted for each group.
1 to 20 of 21
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo-Controlled Period: Imsidolimab 400/200 mg | 0 | 50 |
| Total, all-cause mortality | Placebo-Controlled Period: Imsidolimab 200/100 mg | 0 | 50 |
| Total, all-cause mortality | Placebo-Controlled Period: Placebo | 0 | 49 |
| Total, all-cause mortality | Extension Period: Imsidolimab 400/200 mg | 0 | 40 |
| Total, all-cause mortality | Extension Period: Imsidolimab 200/100 mg | 0 | 42 |
| Total, all-cause mortality | Extension Period: Placebo to Imsidolimab 400/200 mg | 0 | 19 |
| Total, all-cause mortality | Extension Period: Placebo to Imsidolimab 200/100 mg | 0 | 21 |
| Total, other adverse events | Placebo-Controlled Period: Imsidolimab 400/200 mg | 5 | 50 |
| Total, other adverse events | Placebo-Controlled Period: Imsidolimab 200/100 mg | 6 | 50 |
| Total, other adverse events | Placebo-Controlled Period: Placebo | 9 | 49 |
| Total, other adverse events | Extension Period: Imsidolimab 400/200 mg | 9 | 40 |
| Total, other adverse events | Extension Period: Imsidolimab 200/100 mg | 10 | 42 |
| Total, other adverse events | Extension Period: Placebo to Imsidolimab 400/200 mg | 9 | 19 |
| Total, other adverse events | Extension Period: Placebo to Imsidolimab 200/100 mg | 5 | 21 |
| Total, serious adverse events | Placebo-Controlled Period: Imsidolimab 400/200 mg | 0 | 50 |
| Total, serious adverse events | Placebo-Controlled Period: Imsidolimab 200/100 mg | 2 | 50 |
| Total, serious adverse events | Placebo-Controlled Period: Placebo | 3 | 49 |
| Total, serious adverse events | Extension Period: Imsidolimab 400/200 mg | 0 | 40 |
| Total, serious adverse events | Extension Period: Imsidolimab 200/100 mg | 1 | 42 |
| Total, serious adverse events | Extension Period: Placebo to Imsidolimab 400/200 mg | 0 | 19 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04856930/event-totals